0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-2W15676
Home | Market Reports | Health| Health Conditions| Cancer
Global Cell Free Circulating Tumor DNA ctDNA Market Research Report 2023
BUY CHAPTERS

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024

Code: QYRE-Auto-2W15676
Report
August 2024
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cell-Free Circulating Tumor DNA (ctDNA) Market

Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.
The global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cell-Free Circulating Tumor DNA (ctDNA) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cell-Free Circulating Tumor DNA (ctDNA) include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cell-Free Circulating Tumor DNA (ctDNA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell-Free Circulating Tumor DNA (ctDNA).

Report Scope

The Cell-Free Circulating Tumor DNA (ctDNA) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cell-Free Circulating Tumor DNA (ctDNA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cell-Free Circulating Tumor DNA (ctDNA) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Cell-Free Circulating Tumor DNA (ctDNA) Market Report

Report Metric Details
Report Name Cell-Free Circulating Tumor DNA (ctDNA) Market
Segment by Type
  • Gastric Cancer Methylation Screening
  • Esophageal Cancer Methylation Screening
  • Colorectal Cancer Methylation Screening
  • Lung Cancer Methylation Screening
  • Liver Cancer Methylation Screening
  • Other Cancer Screening
Segment by Application
  • Hospital
  • Medical Center
  • Laboratory
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market are Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech

What are the Application segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The Applications covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report are Hospital, Medical Center, Laboratory

What are the Type segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The Types covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report are Gastric Cancer Methylation Screening, Esophageal Cancer Methylation Screening, Colorectal Cancer Methylation Screening, Lung Cancer Methylation Screening, Liver Cancer Methylation Screening, Other Cancer Screening

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gastric Cancer Methylation Screening
1.2.3 Esophageal Cancer Methylation Screening
1.2.4 Colorectal Cancer Methylation Screening
1.2.5 Lung Cancer Methylation Screening
1.2.6 Liver Cancer Methylation Screening
1.2.7 Other Cancer Screening
1.3 Market by Application
1.3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Medical Center
1.3.4 Laboratory
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Perspective (2019-2030)
2.2 Cell-Free Circulating Tumor DNA (ctDNA) Growth Trends by Region
2.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Region (2019-2024)
2.2.3 Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2025-2030)
2.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics
2.3.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends
2.3.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers
2.3.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges
2.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue
3.1.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue (2019-2024)
3.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Players (2019-2024)
3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell-Free Circulating Tumor DNA (ctDNA) Revenue
3.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio
3.4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023
3.5 Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Area Served
3.6 Key Players Cell-Free Circulating Tumor DNA (ctDNA) Product Solution and Service
3.7 Date of Enter into Cell-Free Circulating Tumor DNA (ctDNA) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Type
4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Type (2019-2024)
4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2025-2030)
5 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Application
5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Application (2019-2024)
5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)
6.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)
6.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)
7.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)
7.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)
8.2 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024)
8.4 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)
9.2 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)
9.4 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)
10.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)
10.4 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nexomics
11.1.1 Nexomics Company Detail
11.1.2 Nexomics Business Overview
11.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.1.4 Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.1.5 Nexomics Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.2.4 Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.2.5 Roche Recent Development
11.3 ORIOMICS
11.3.1 ORIOMICS Company Detail
11.3.2 ORIOMICS Business Overview
11.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.3.4 ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.3.5 ORIOMICS Recent Development
11.4 Signatera
11.4.1 Signatera Company Detail
11.4.2 Signatera Business Overview
11.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.4.4 Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.4.5 Signatera Recent Development
11.5 Illumina
11.5.1 Illumina Company Detail
11.5.2 Illumina Business Overview
11.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.5.4 Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.5.5 Illumina Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Detail
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.6.4 Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.6.5 Sysmex Corporation Recent Development
11.7 Bio-Rad
11.7.1 Bio-Rad Company Detail
11.7.2 Bio-Rad Business Overview
11.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.7.4 Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.7.5 Bio-Rad Recent Development
11.8 Biocartis
11.8.1 Biocartis Company Detail
11.8.2 Biocartis Business Overview
11.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.8.4 Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.8.5 Biocartis Recent Development
11.9 QIAGEN
11.9.1 QIAGEN Company Detail
11.9.2 QIAGEN Business Overview
11.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.9.4 QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.9.5 QIAGEN Recent Development
11.10 GuardantHealth
11.10.1 GuardantHealth Company Detail
11.10.2 GuardantHealth Business Overview
11.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.10.4 GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.10.5 GuardantHealth Recent Development
11.11 GSK plc
11.11.1 GSK plc Company Detail
11.11.2 GSK plc Business Overview
11.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.11.4 GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.11.5 GSK plc Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Detail
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.12.4 AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.12.5 AstraZeneca Recent Development
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Detail
11.13.2 NeoGenomics Laboratories Business Overview
11.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.13.4 NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.13.5 NeoGenomics Laboratories Recent Development
11.14 AmoyDx
11.14.1 AmoyDx Company Detail
11.14.2 AmoyDx Business Overview
11.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.14.4 AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.14.5 AmoyDx Recent Development
11.15 Annoroad
11.15.1 Annoroad Company Detail
11.15.2 Annoroad Business Overview
11.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.15.4 Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.15.5 Annoroad Recent Development
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Detail
11.16.2 Burning Rock Biotech Business Overview
11.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Introduction
11.16.4 Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
11.16.5 Burning Rock Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Gastric Cancer Methylation Screening
    Table 3. Key Players of Esophageal Cancer Methylation Screening
    Table 4. Key Players of Colorectal Cancer Methylation Screening
    Table 5. Key Players of Lung Cancer Methylation Screening
    Table 6. Key Players of Liver Cancer Methylation Screening
    Table 7. Key Players of Other Cancer Screening
    Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (US$ Million)
    Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2019-2024)
    Table 12. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2025-2030)
    Table 14. Cell-Free Circulating Tumor DNA (ctDNA) Market Trends
    Table 15. Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers
    Table 16. Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges
    Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints
    Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players (2019-2024) & (US$ Million)
    Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players (2019-2024)
    Table 20. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2023)
    Table 21. Ranking of Global Top Cell-Free Circulating Tumor DNA (ctDNA) Companies by Revenue (US$ Million) in 2023
    Table 22. Global 5 Largest Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue (CR5 and HHI) & (2019-2024)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Cell-Free Circulating Tumor DNA (ctDNA) Product Solution and Service
    Table 25. Date of Enter into Cell-Free Circulating Tumor DNA (ctDNA) Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2019-2024) & (US$ Million)
    Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2019-2024)
    Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2025-2030)
    Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2019-2024) & (US$ Million)
    Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2019-2024)
    Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2025-2030)
    Table 35. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
    Table 37. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
    Table 40. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
    Table 41. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 42. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (US$ Million)
    Table 43. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2025-2030) & (US$ Million)
    Table 44. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
    Table 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 48. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
    Table 50. Nexomics Company Detail
    Table 51. Nexomics Business Overview
    Table 52. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 53. Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 54. Nexomics Recent Development
    Table 55. Roche Company Detail
    Table 56. Roche Business Overview
    Table 57. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 58. Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 59. Roche Recent Development
    Table 60. ORIOMICS Company Detail
    Table 61. ORIOMICS Business Overview
    Table 62. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 63. ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 64. ORIOMICS Recent Development
    Table 65. Signatera Company Detail
    Table 66. Signatera Business Overview
    Table 67. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 68. Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 69. Signatera Recent Development
    Table 70. Illumina Company Detail
    Table 71. Illumina Business Overview
    Table 72. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 73. Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 74. Illumina Recent Development
    Table 75. Sysmex Corporation Company Detail
    Table 76. Sysmex Corporation Business Overview
    Table 77. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 78. Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 79. Sysmex Corporation Recent Development
    Table 80. Bio-Rad Company Detail
    Table 81. Bio-Rad Business Overview
    Table 82. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 83. Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 84. Bio-Rad Recent Development
    Table 85. Biocartis Company Detail
    Table 86. Biocartis Business Overview
    Table 87. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 88. Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 89. Biocartis Recent Development
    Table 90. QIAGEN Company Detail
    Table 91. QIAGEN Business Overview
    Table 92. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 93. QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 94. QIAGEN Recent Development
    Table 95. GuardantHealth Company Detail
    Table 96. GuardantHealth Business Overview
    Table 97. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 98. GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 99. GuardantHealth Recent Development
    Table 100. GSK plc Company Detail
    Table 101. GSK plc Business Overview
    Table 102. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 103. GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 104. GSK plc Recent Development
    Table 105. AstraZeneca Company Detail
    Table 106. AstraZeneca Business Overview
    Table 107. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 108. AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 109. AstraZeneca Recent Development
    Table 110. NeoGenomics Laboratories Company Detail
    Table 111. NeoGenomics Laboratories Business Overview
    Table 112. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 113. NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 114. NeoGenomics Laboratories Recent Development
    Table 115. AmoyDx Company Detail
    Table 116. AmoyDx Business Overview
    Table 117. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 118. AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 119. AmoyDx Recent Development
    Table 120. Annoroad Company Detail
    Table 121. Annoroad Business Overview
    Table 122. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 123. Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 124. Annoroad Recent Development
    Table 125. Burning Rock Biotech Company Detail
    Table 126. Burning Rock Biotech Business Overview
    Table 127. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product
    Table 128. Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
    Table 129. Burning Rock Biotech Recent Development
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type: 2023 VS 2030
    Figure 3. Gastric Cancer Methylation Screening Features
    Figure 4. Esophageal Cancer Methylation Screening Features
    Figure 5. Colorectal Cancer Methylation Screening Features
    Figure 6. Lung Cancer Methylation Screening Features
    Figure 7. Liver Cancer Methylation Screening Features
    Figure 8. Other Cancer Screening Features
    Figure 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application: 2023 VS 2030
    Figure 11. Hospital Case Studies
    Figure 12. Medical Center Case Studies
    Figure 13. Laboratory Case Studies
    Figure 14. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered
    Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2023 VS 2030
    Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players in 2023
    Figure 19. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2023)
    Figure 20. The Top 10 and 5 Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023
    Figure 21. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
    Figure 23. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
    Figure 27. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2019-2030)
    Figure 35. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
    Figure 43. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
    Figure 47. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Nexomics Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 50. Roche Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 51. ORIOMICS Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 52. Signatera Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 53. Illumina Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 54. Sysmex Corporation Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 55. Bio-Rad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 56. Biocartis Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 57. QIAGEN Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 58. GuardantHealth Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 59. GSK plc Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 60. AstraZeneca Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 61. NeoGenomics Laboratories Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 62. AmoyDx Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 63. Annoroad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 64. Burning Rock Biotech Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Anti-Oral Mucositis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-5V5924
Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-18Y13983
Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-37R6886
Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Global Heavy Ion Radiotherapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-9J14338
Sun Oct 06 00:00:00 UTC 2024

Add to Cart